Posted by Michael Wonder on 13 Nov 2021
FDA approves treatment for rare blood disease
12 November 2021 - Treatment is first FDA approved option patients can take regardless of previous therapies.
Today, the U.S. Food and Drug Administration approved Besremi (ropeginterferon alfa-2b-njft) injection to treat adults with polycythemia vera, a blood disease that causes the overproduction of red blood cells.
